Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 20, 2014, 02:43:34 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 642785
  • Total Topics: 48897
  • Online Today: 221
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Electric pore Vaccine opens cell membranes, gives access to the nucleus  (Read 2322 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
this is a major breakthrough...

This technique involves delivering a short burst of electrical stimulation to the area where the DNA vaccine is injected using a special wand. The electricity opens transient pores in local cell membranes, allowing the DNA vaccine easier access to the nucleus where it can then produce vaccine-encoded antigens. Furthermore, electroporation also attracts inflammatory cells - including antigen-presenting dendritic cells - to the site of immunization. The new study reports that electroporation massively enhanced the T cell response to an SIV DNA vaccine in macaques.  Specifically, although animals receiving electroporation were given 1/5 the DNA vaccine dose, SIV-specific T cell responses were 10-40 fold higher than those seen in macaques immunized with DNA vaccines alone. The study authors note that while electroporation seemed safe in macaques, the question of safety and tolerability in humans will need to be comprehensively addressed in phase I trials.

Inovio: DNA delivery technology lifts HIV vaccine potency

LONDON (MarketWatch) -- Inovio Biomedical Corp. (INO :
inovio biomedical corp com said that a scientific paper prepared by Inovio's development partner, Wyeth, showed results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical's electroporation technology. The study showed that non-human primate data demonstrated a significant increase in both the breadth and magnitude of cellular immune response to selected HIV antigens, the company said. The results indicated that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates, the paper said 10-40 fold higher than those seen in macaques immunized with DNA vaccines alone.



http://www.google.com/search?hl=en&q=+Inovio+HIV&btnG=Google+Search
innovo and HIV

http://www.medicalnewstoday.com/medicalnews.php?newsid=66137

http://tagbasicscienceproject.typepad.com/tags_basic_science_vaccin/

Wyeth Reports Electrifying DNA Vaccine Results

In the early 1990s, vaccine researchers were surprised to discover that simply injecting DNA sequences encoding protein antigens could induce substantial immune responses in mice. For a time there was a great deal of excitement about the potential of these "naked DNA" vaccines, particularly because they are extremely cheap and easy to produce. However, as studies escalated into larger animals and humans, it quickly became apparent that the immunogenicity of the vaccines declined dramatically in these settings. Several candidates abjectly failed to induce detectable immune reponses in humans. Nevertheless, researchers have continued to work on improving DNA vaccine immunogenicity and recent phase I trial results from NIH's Vaccine Research Center suggest that HIV DNA vaccines delivered by a needle-free device called a Biojector can be a viable component of a prime-boost vaccine regimen. In parallel, researchers at Wyeth Vaccines have also been exploring ways to soup up their DNA vaccine candidates. Inclusion of "molecular adjuvants" (such as genes encoding potentially  immune-boosting cytokines like IL-12 and IL-15) is one strategy Wyeth has explored, with some incremental improvements seen when IL-12 DNA is delivered along with an HIV DNA vaccine.

Now, in J. Virology, Wyeth researchers report far more dramatic results obtained using a technique called electroporation. This technique involves delivering a short burst of electrical stimulation to the area where the DNA vaccine is injected using a special wand. The electricity opens transient pores in local cell membranes, allowing the DNA vaccine easier access to the nucleus where it can then produce vaccine-encoded antigens. Furthermore, electroporation also attracts inflammatory cells - including antigen-presenting dendritic cells - to the site of immunization. The new study reports that electroporation massively enhanced the T cell response to an SIV DNA vaccine in macaques.  Specifically, although animals receiving electroporation were given 1/5 the DNA vaccine dose, SIV-specific T cell responses were 10-40 fold higher than those seen in macaques immunized with DNA vaccines alone. The study authors note that while electroporation seemed safe in macaques, the question of safety and tolerability in humans will need to be comprehensively addressed in phase I trials. The manufacturers of the technology used in this study, Inovio, issued an accompanying press release which states that they are also collaborating with other partners and several human trials of DNA vaccines and immunotherapies combined with their electroporation device are ongoing. Results from these trials should reveal whether electroporation can safely give DNA vaccines the zap they need.


an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio's development partner, Wyeth, regarding results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical's electroporation technology. The paper, titled "Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques," summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: "These results indicate that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates. Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."
« Last Edit: April 03, 2007, 06:42:34 PM by bimazek »

Offline J.R.E.

  • Member
  • Posts: 7,212
  • Joined Dec-2003 Living positive, since 1985.
Biz,


Your second link down , needs fixing,


Ray
Current Meds ; Viramune, Epzicom, 40mg of simvastatin, 12.5mg of Hydrochlorothiazide.
Metoprolol tartrate 25mg



http://forums.poz.com/index.php?topic=40802.0

http://forums.poz.com/index.php?topic=45159.0

http://forums.poz.com/index.php?topic=39722.msg495621;topicseen#msg495621

http://forums.poz.com/index.php?topic=46806.0

http://forums.poz.com/index.php?topic=39414.msg491701#msg491701


 In October of 2003, My t-cell count was 16, Viral load was over 500,000, Percentage at that time was 5%. I started my first  HAART regimen  on October 24th,03.

 As of 8/2514,  t-cells are at 402, Viral load <40

 Current % is at 11%

  
 62 years young.

Offline bimazek

  • Member
  • Posts: 781
 an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio's development partner, Wyeth, regarding results from a non-human primate study of an investigational DNA vaccine against HIV delivered using Inovio Biomedical's electroporation technology. The paper, titled "Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques," summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: "These results indicate that in vivo electroporation appears safe and can dramatically improve the delivery and immunogenicity of a multi-vector, multi-antigen pDNA vaccine in non-human primates. Collectively, these data have important implications for the design and development of an efficacious therapeutic vaccine for the treatment of HIV-1 infection."

Key observations of the study included:

-- Vaccination in combination with in vivo electroporation led to a more rapid onset and enhanced vaccine-specific immune responses.

-- This increase in CMI (cell-mediated immune) responses translates to an apparent 50-200-fold (8 weeks and 22 weeks, respectively) increase in pDNA (plasmid DNA) vaccine potency.

-- Importantly, in vivo electroporation enhanced the immune response against the less immunogenic antigens, resulting in a more balanced immune response.

-- In addition, in vivo electroporation resulted in an approximate 2.5 log10 increase in antibody responses.

"Wyeth's non-human primate data demonstrated a significant increase in both the breadth and magnitude of the cellular immune response to selected HIV antigens. This is the type of response that virologists have been seeking for many years," stated Avtar Dhillon, MD, president and CEO of Inovio. "While these data will need to be reproduced in human clinical trials, the significant enhancement in potency observed to date reaffirms our position that electroporation is a key enabling technology for DNA vaccines."

Inovio's collaboration and non-exclusive license agreement with Wyeth was announced in November 2006.

About Inovio's DNA Delivery Technology
« Last Edit: April 03, 2007, 09:56:18 PM by bimazek »

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: Electric pore Vaccine opens cell membranes, gives access to the nucleus
« Reply #3 on: October 20, 2009, 11:49:28 AM »
Inovio begins HIV trial for DNA vaccine delivered using electroporation

Tuesday, October 20, 2009 18:00 IST
San Diego

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced the initiation of a phase-I clinical study of Inovio's Pennvax-B preventive DNA vaccine delivered using its proprietary electroporation technology. The multi-centre study will be conducted at several HVTN clinical sites under a protocol designated HVTN-080.

The study will enrol healthy volunteers to assess the safety of and immune responses to this DNA-based vaccine delivered via in vivo electroporation. Inovio previously reported data from non-human primates demonstrating up to a 100-fold enhancement in immune responses resulting from the vaccine when delivered via in vivo electroporation compared to syringe injection without electroporation. Pennvax-B is currently in a clinical study, being conducted under the HVTN-070 protocol by the same group of collaborators, to test safety and immunogenicity of the vaccine delivered via intramuscular syringe injection without electroporation. The HVTN-080 follow-on study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), an NIH agency.

Dr J Joseph Kim, Inovio's president and CEO, said, "We are pleased to collaborate with the NIH and HVTN to test the SynCon Pennvax-B HIV vaccine delivered via electroporation. With our recently announced positive interim immunogenicity data from our clinical trial for our human papillomavirus/cervical cancer DNA vaccine using a similar technology approach, we are optimistic that electroporation delivery of Pennvax-B vaccine will demonstrate similar levels of safety and immunogenicity in this trial."

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases.   


LINK:

http://www.pharmabiz.com/article/detnews.asp?articleid=52201&sectionid=

Offline veritas

  • Member
  • Posts: 1,410
Re: Electric pore Vaccine opens cell membranes, gives access to the nucleus
« Reply #4 on: October 20, 2009, 01:52:05 PM »

Inch,

This sounds intriging. Here's somemore info from their websight:

http://ir.inovio.com/phoenix.zhtml?c=105128&p=irol-newsArticle&ID=1343789&highlight=

I like the "stuff" going on in vaccine research lately!

v

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.